Biologics and biosimilars balancing incentives for innovation : hearing before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, House of Representatives, One Hundred Eleventh Congress, first session, July 14, 2009

Guidance for industry and FDA staff early development considerations for innovative combination products

Guidance for sponsors, industry, researchers, investigators, and Food and Drug Administration staff certifications to accompany drug, biological product and device applications/submissions : compliance with Section 402(j) of the Public Health Service Act, added by Title VIII of the Food and Drug Administration Amendments Act of 2007

Review of controls over the export of chemical and biological commodities (redacted)

Biological incident annex to the Response and Recovery Federal interagency operational plans

Aquatic life criteria for dissolved oxygen (saltwater) Cape Cod to Cape Hatteras-fact sheet

Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012

Assessing the biological weapons and bioterrorism threat

Purchasing perspective : VA's prosthetics paradox : hearing before the Subcommittee on Oversight and Investigations of the Committee on Veterans' Affairs, U.S. House of Representatives, One Hundred Twelfth Congress, second session, Wednesday, May 30, 2012

Biological research for energy and medical applications at the Department of Energy Office of Science : hearing before the Subcommittee on Energy and Environment, Committee on Science and Technology, House of Representatives, One Hundred Eleventh Congress, first session, September 10, 2009